[Radioimmunoimaging of hepatocellular carcinoma with 131I labeled antihepatoma monoclonal antibody Fab fragment].
To study the effects of radioimmunoimaging (R11) of hepatocellular carcinoma with 131I labeled antihepatoma monoclonal antibody (HAb18) Fab fragment. HAb18Fab was prepared by papain digesting HAb18, and it was radioiodinated with iodine-131 using high efficiency iodination method. The experiment consisted of two parts: ten nud mice bearing human hepatocellular carcinoma xenograft were injected intravenously with 131I-HAb18Fab 3,700 kBq/mouse, and six patients with hepatocellular carcinoma were injected intravenously with 131I-HAb18Fab 111-166.5 mBq/body. Ten nud mice bearing hepatocellular carcinoma, showed positive image. The optimum imaging time was 4.5-12 h after injection, and was 21.07 +/- 0.05 for tumor/liver higher than 5.83 +/- 0.05 of intact HAb18, and the reported 3.03. No tumor image was found in the control group of mice. Six patients with hepatocellular carcinoma, after injecting 131I-HAb18Fab 16 h, showed positive image. The optimum imaging time was 16-24 h earlier than 96 h of the reported 131I. R11 with 131I-HAb18Fab possesses the advantages of the location, qualitative analysis and earlier diagnosis. It is prospective in clinical application.